AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01345812
Drug: HP-HMG
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 - 300 IU for stimulation of women in ART treatment
Trial: NCT01345812
Drug: recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 -300 IU for stimulation of women in ART treatment
Trial: NCT02256813
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02188784
Drug: Polysaccharide Iron Complex 150 mg
RxNorm normalized name: polysaccharide iron complex 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Iron
Trial: NCT02188784
Drug: Placebo (for Polysaccharide Iron Complex)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar capsule designed to mimic Polysaccharide Iron Complex.
Trial: NCT02070289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, BID, 14 days
Trial: NCT02070289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, BID or titration, 14 days
Trial: NCT00276016
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules
Trial: NCT00005067
Drug: photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo photodynamic therapy
Trial: NCT01388933
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15g as 5g three times daily, orally for 8 consecutive weeks
Trial: NCT01843699
Drug: Placebo matching tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00665106
Drug: NOVA63035 Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection in the study eye
Trial: NCT00990821
Drug: 90 mg MK-0517 (PS80)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
Trial: NCT00990821
Drug: 100 mg MK-0517 (PS80)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Trial: NCT00990821
Drug: 115 mg MK-0517 (PS80)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Trial: NCT00990821
Drug: 150 mg MK-0517 (PS80)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Trial: NCT00990821
Drug: 40 mg MK-0517 (non-PS80)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
Trial: NCT00990821
Drug: 100 mg MK-0517 (non-PS80)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
Trial: NCT00990821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching MK-0517
Trial: NCT02251821
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02251821
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01033097
Drug: DNK333 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral
Trial: NCT01033097
Drug: Placebo to 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg placebo oral
Trial: NCT01033097
Drug: DNK333 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral
Trial: NCT01033097
Drug: Placebo to 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg placebo oral
Trial: NCT01033097
Drug: DNK333 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral
Trial: NCT01033097
Drug: Placebo to 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg placebo oral
Trial: NCT01033097
Drug: DNK333 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral
Trial: NCT01033097
Drug: Placebo to 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg placebo oral
Trial: NCT04372186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.
Trial: NCT02648282
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg/m2 as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 6 months for an additional 4 doses.
Trial: NCT00946998
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet will be identical and matched to sertraline tablet.
Trial: NCT02936492
Drug: BAY1003803 0.01% lipophilic cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration for 22 h per day
Trial: NCT02936492
Drug: BAY1003803 0.1% lipophilic cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration for 22 h per day
Trial: NCT02936492
Drug: BAY1003803 0.01% ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration for 22 h per day
Trial: NCT02936492
Drug: BAY1003803 0.1% ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration for 22 h per day
Trial: NCT04621058
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules exactly the same as the above, but without the active component.
Trial: NCT02306213
Drug: Hydroxyethylstarch 6% 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
Trial: NCT01314898
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg spironolactone, single oral dose
Trial: NCT03698617
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
Trial: NCT02983890
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned
Trial: NCT02591914
Drug: Fovista™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PDGF-B pegylated aptamer
Trial: NCT02591914
Drug: Lucentis®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-VEGF
Trial: NCT02591914
Drug: Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-VEGF
Trial: NCT02591914
Drug: Eylea®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-VEGF
Trial: NCT00420563
Drug: CYCLOPHOSPHAMIDE
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
Trial: NCT00282828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092313
Drug: MK0966, rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092313
Drug: Comparator: oxycodone and acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04276636
Drug: Caltrate Pill
RxNorm normalized name: Caltrate Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
Trial: NCT01779557
Drug: Huaren Peritoneal Dialysate
RxNorm normalized name: PERITONEAL DIALYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaren Peritoneal dialysate CAPD 3-5 times/d
Trial: NCT01779557
Drug: Baxter Peritoneal Dialysate
RxNorm normalized name: PERITONEAL DIALYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxter Peritoneal dialysate CAPD 3-5 times/d
Trial: NCT02312609
Drug: Minocycline hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: extended release tablets 135 mg
Trial: NCT02733835
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
Trial: NCT01602003
Drug: LC15-0444 25mg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
Trial: NCT02773407
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02773407
Drug: Co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01635621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
Trial: NCT03087851
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion of 5 mg zoledronic acid
Trial: NCT02679079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00359684
Drug: Cysteamine
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystine-depleting agent
Trial: NCT01812707
Drug: Placebo (for alirocumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen
Trial: NCT00002878
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01769352
Drug: PredA + Kelac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
Trial: NCT02339506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
Trial: NCT01118013
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02464046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
Trial: NCT04531150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive placebo tablets
Trial: NCT02894385
Drug: BAY1841788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
Trial: NCT02912559
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02912559
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03441789
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle foam applied to affected areas once daily
Trial: NCT03328104
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 440 mg/m2 IV x Day 1-5
Trial: NCT03792035
Drug: Tongxinluo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tid, po.
Trial: NCT03792035
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tid, po.
Trial: NCT00676429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as oral solution, individually titrated
Trial: NCT04581772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT01732926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally twice daily
Trial: NCT02490878
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02544113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal transplant immunosuppression
Trial: NCT01023308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered 3x week ( 2 weeks on 1 week off)
Trial: NCT00337415
Drug: MK0354
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02734953
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ambulatory inhaled nitric oxide delivery system and 6 minute walk distance test
Trial: NCT03728153
Drug: Fluoxetine 20 MG Oral Tablet
RxNorm normalized name: fluoxetine 20 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing for 90 days
Trial: NCT01087723
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04017949
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cc (40 mg) of a corticosteroid (kenalog) is given
Trial: NCT01074437
Drug: Prednisolone (Corticosteroid)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
Trial: NCT01074437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid placebo will be given during the two month treatment trial.
Trial: NCT03896620
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of chemotherapy.
Trial: NCT03321877
Drug: Change to dose of patient's regular medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction of the drug each patient was already taking
Trial: NCT03172741
Drug: Medical Marijuana
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-gram marijuana cigarette smoked once per day for 3 months
Trial: NCT03172741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching 1 gram placebo cigarette smoked once per day for 3 months
Trial: NCT01281553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
Trial: NCT03585114
Drug: [F-18] DCFPyL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of \[18F\]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).
Trial: NCT04494425
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
Trial: NCT02701582
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \< 2.2 Epinephrine is administered
Trial: NCT03270579
Drug: [18F]JNJ-64511070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An IV injection of 185 MBq \[18F\]JNJ-64511070 will be administered.
Trial: NCT02343978
Drug: KWA-0711
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03199261
Drug: rE-4 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
Trial: NCT02396498
Drug: HIPEC
RxNorm normalized name: Hyperthermic Intraperitoneal Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using cisplatin in HIPEC plus oral S-1
Trial: NCT02995733
Drug: PARTICS using QVAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient takes inhaled corticosteroid at the time of rescue inhaler use
Trial: NCT00981929
Drug: Omeprazole, losartan, caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole 25 mg losartan 200 mg caffeine
Trial: NCT00981929
Drug: Tramadol, omeprazole, losartan, caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
Trial: NCT00209222
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy
Trial: NCT04044976
Drug: Caffeine Citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infants will receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth.
Trial: NCT00209222
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: NCT02091206
Drug: GWP42003-P 5 mg/kg/day Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Trial: NCT02026973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02005029
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02005029
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02307162
Drug: RPL554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase 3 and 4 Inhibitor
Trial: NCT05191186
Drug: Grass pollen extract - Alutard Phleum pratense, ALK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection in lymph node
Trial: NCT04501107
Drug: Administration of US-approved Humalog® (IMP3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of IMP3 during a 12-hour euglycaemic clamp.
Trial: NCT04501107
Drug: Administration of EU-approved Humalog® (IMP4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of IMP4 during a 12-hour euglycaemic clamp.
Trial: NCT02642159
Drug: Antihyperglycemic Drug
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
Trial: NCT01961804
Drug: Reversion
RxNorm normalized name: Reversion Acne Control Toner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of prothrombin complex concentrates: KANOKAD before CT Scan
Trial: NCT01039558
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
Trial: NCT01370161
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed.